Exon 20 Group GFR/HER2 Exon 20 Mutation Group

The Exon 20 EGFR/HER2 Mutation Group

If so, we cordially invite you to join us in launching the EGFR/HER2 Exon 20 Group—working toward turning these rare diagnoses into manageable chronic diseases. This international group comprises multiple constituencies:

  • Patients and Families
  • Oncologists
  • Researchers
  • Patient Advocacy Organizations
  • National Cancer Institute Scientists
  • Biopharmaceutical Companies
  • Laboratory Medicine (including Pathology and Molecular Profiling)

Please enjoy the first issue of INDELible News - the Exon 20 Group newsmagazine

(Flipbook ) or (PDF version)

Most importantly, the Exon 20 Group is dedicated to expediting exon 20-targeted drugs into—and through—clinical trials, to benefit patients and the global oncology community. To that end, the Exon 20 Group will work to accelerate the discovery and the rapid approval of promising exon 20-targeted agents—along with immunotherapeutic agents—and rapidly cycle those agents into multiple combination clinical trials. Ultimately, the group also seeks to help establish best practices for the use of tissue and liquid biopsy in exon 20 patients.

By joining us—and there is no membership fee—you will receive our complimentary newsletter and e-blasts to stay informed about important developments. With the power of all stakeholders in the Exon 20 Group, we can succeed in accelerating the development of innovative therapies for exon 20 lung cancer.

Please help us spread the word!


Kevin Hanlon
Founder and Exon 20 insertion patient

The EGFR/HER2 Exon 20 Group abides by the highest standards of patient privacy and is zealously HIPAA-compliant. Your contact information will not be shared with third parties. ICAN®, International Cancer Advocacy Network (https://askican.org) is a highly acclaimed, five star and Platinum-rated 501(c)(3) cancer patient advocacy organization serving patients across the U.S. and around the world. With the assistance of experts on its various professional councils, ICAN (ICAN is totally independent of any cancer center, research institute, lab, or biopharma company) is collecting information that could lead drug developers to more fully understand these rare exon 20 targeted agents and expedite clinical trials of those agents in combination with other drugs. In short, Exon 20 Group and ICAN are working to accelerate the drug pipeline in EGFR/HER2 exon 20 mutations.